Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adicet Bio, Inc.

0.5684
+0.04268.10%
Post-market: 0.57000.0016+0.28%18:30 EDT
Volume:293.94K
Turnover:158.36K
Market Cap:47.00M
PE:-0.43
High:0.5684
Open:0.5570
Low:0.5114
Close:0.5258
Loading ...

Company Profile

Company Name:
Adicet Bio, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
152
Office Location:
131 Dartmouth Street,3rd Floor,Boston,Massachusetts,United States
Zip Code:
02116
Fax:
- -
Introduction:
resTORbio, Inc., a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. has collaboration with TrialSpark to investigate RTB-101 for COVID-19 on the Project Covalence platform. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Chen Schor
Director, President and Chief Executive Officer
Andrew Sinclair
Director
Aya Jakobovits
Director
Bastiano Sanna
Director
Carl L. Gordon
Director
Jeffrey Chodakewitz
Director
Steve Dubin
Director

Shareholders

Name
Position
Chen Schor
Director, President and Chief Executive Officer
Nick Harvey
Chief Financial Officer
Carrie Krehlik
Chief Human Resource Officer
Don Healey
Chief Technology Officer
Francesco Galimi
Chief Medical Officer
Stewart Abbot
Chief Scientific and Operating Officer